The expression level of microRNA-107 (miR-107) has been proved to be decreased in many human malignant cancers. Especially in glioma, accumulating evidence indicates that miR-107 may play important parts in cell proliferation, apoptosis, and invasion in glioma. However, its clinical significance in glioma has not been investigated. This study aims at investigating the relationship between miR-107 expression level and clinical significance and analyzing its value of miR-107 in valuing the prognosis of glioma patients. Quantitative real-time polymerase chain reaction (qRT-PCR) was used to measure the expression of miR-107 in 80 glioma and 17 normal brain tissues. The results showed the miR-107 expression level in glioma tissues was significantly lower than those in normal brain tissues (p < 0.001). The decreased expression of miR-107 in glioma was positively associated with high WHO grade (p < 0.001), low Karnofsky performance score (KPS) (p < 0.001), and large tumor size (p < 0.001) and had a significant impact on overall survival (OS) (p < 0.001) and progression-free survival (PFS) (p < 0.001) according to Kaplan–Meier survival with log-rank test. Finally, Cox regression analyses showed that low miR-107 expression (p < 0.001) might be an independent prognostic parameter to predict poor prognosis. In conclusion, it is the first data to prove that expression level of miR-107 may be a novel and valuable prognostic factor in glioma.
This is a preview of subscription content, log in to check access.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
This article does not contain any studies with animals performed by any of the authors.
Additional informed consent was obtained from all individual participants for whom identifying information is included in this article.
Gao H, Zhao H, Xiang W. Expression level of human miR-34a correlates with glioma grade and prognosis. J Neurooncol. 2013;113:221–8.CrossRefPubMedGoogle Scholar
Men D, Liang Y, Chen L. Decreased expression of microRNA-200b is an independent unfavorable prognostic factor for glioma patients. Cancer Epidemiol. 2014;38:152–6.CrossRefPubMedGoogle Scholar
Wang S, Lu S, Geng S, Ma S, Liang Z, Jiao B. Decreased expression of microRNA-206 correlates with poor clinical outcome in patients with malignant astrocytomas. Pathol Oncol Res 2014.Google Scholar
He J, Deng Y, Yang G, Xie W. MicroRNA-203 down-regulation is associated with unfavorable prognosis in human glioma. J Surg Oncol. 2013;108:121–5.CrossRefPubMedGoogle Scholar
Lai NS, Dong QS, Ding H, Miao ZL, Lin YC. MicroRNA-210 overexpression predicts poorer prognosis in glioma patients. J Clin Neurosci. 2014;21:755–60.CrossRefPubMedGoogle Scholar
Sun J, Shi H, Lai N, Liao K, Zhang S, Lu X. Overexpression of microRNA-155 predicts poor prognosis in glioma patients. Med Oncol. 2014;31:911.CrossRefPubMedGoogle Scholar
Wu Z, Wang L, Li G, Liu H, Fan F, Li Z, et al. Increased expression of microRNA-9 predicts an unfavorable prognosis in human glioma. Mol Cell Biochem. 2013;384:263–8.CrossRefPubMedGoogle Scholar
Sun B, Pu B, Chu D, Chu X, Li W, Wei D. MicroRNA-650 expression in glioma is associated with prognosis of patients. J Neuro-Oncol. 2013;115:375–80.CrossRefGoogle Scholar
Chen L, Chen X, Zhang R, Li P, Liu Y, Yan K, et al. MicroRNA-107 inhibits glioma cell migration and invasion by modulating Notch2 expression. J Neuro-Oncol. 2013;112:59–66.CrossRefGoogle Scholar
He J, Zhang W, Zhou Q, Zhao T, Song Y, Chai L, et al. Low-expression of microRNA-107 inhibits cell apoptosis in glioma by upregulation of SALL4. Int J Biochem Cell Biol. 2013;45:1962–73.CrossRefPubMedGoogle Scholar
Nakazato Y. The 4th edition of WHO classification of tumours of the central nervous system published in 2007. No Shinkei Geka. 2008;36:473–91.PubMedGoogle Scholar
Zhang Y, Dutta A, Abounader R. The role of microRNAs in glioma initiation and progression. Front Biosci (Landmark Ed). 2012;17:700–12.CrossRefGoogle Scholar
Zhong KZ, Chen WW, Hu XY, Jiang AL, Zhao J. Clinicopathological and prognostic significance of microRNA-107 in human non small cell lung cancer. Int J Clin Exp Pathol. 2014;7:4545–51.PubMedPubMedCentralGoogle Scholar
Molina-Pinelo S, Carnero A, Rivera F, Estevez-Garcia P, Bozada JM, Limon ML, et al. Mir-107 and mir-99a-3p predict chemotherapy response in patients with advanced colorectal cancer. BMC Cancer. 2014;14:656.CrossRefPubMedPubMedCentralGoogle Scholar
Feng L, Xie Y, Zhang H, Wu Y. Mir-107 targets cyclin-dependent kinase 6 expression, induces cell cycle G1 arrest and inhibits invasion in gastric cancer cells. Med Oncol. 2012;29:856–63.CrossRefPubMedGoogle Scholar
Datta J, Smith A, Lang JC, Islam M, Dutt D, Teknos TN, et al. Microrna-107 functions as a candidate tumor-suppressor gene in head and neck squamous cell carcinoma by downregulation of protein kinase Cvarepsilon. Oncogene. 2012;31:4045–53.CrossRefPubMedGoogle Scholar
Ayala DLPF, Kanasaki K, Kanasaki M, Tangirala N, Maeda G, Kalluri R. Loss of p53 and acquisition of angiogenic microRNA profile are insufficient to facilitate progression of bladder urothelial carcinoma in situ to invasive carcinoma. J Biol Chem. 2011;286:20778–87.CrossRefGoogle Scholar
Boulay JL, Miserez AR, Zweifel C, Sivasankaran B, Kana V, Ghaffari A, et al. Loss of notch2 positively predicts survival in subgroups of human glial brain tumors. PLoS One. 2007;2:e576.CrossRefPubMedPubMedCentralGoogle Scholar